Alnylam Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the quarter ended June 30, 2026. The company filed a Current Report on Form 8-K on July 30, 2026 reporting these results under Item 2.02 (Results of Operations and Financial Condition). The full press release with the announcement is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: July 30, 2026 (Form 8-K, Accession No. 0001178670-26-000060).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition.
• Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
• Exhibit: Press release announcing the results is furnished as Exhibit 99.1 (Item 9.01).

Why It Matters

• Quarterly financial results contain the company’s revenue, earnings, and other key metrics that can affect ALNY’s stock price and investor outlook. This 8-K signals Alnylam has publicly released its Q2 2026 performance; investors should read Exhibit 99.1 for the detailed figures and any commentary on guidance or business drivers.
• This filing only furnishes the press release and reports results; it does not report executive changes, mergers, or other corporate actions in this 8-K.